Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
June 22, 2015Proceedings of the National Academy of SciencesOpen Access

Selective resistance to the PARP inhibitor olaparib in a mouse model for BRCA1-deficient metaplastic breast cancer

View Full Paper
Ask AI
Bookmark
Share

Authors

LHLinda HennemanOncode InstituteMMMartine H. van MiltenburgThe Netherlands Cancer InstituteEMEwa M. MichalakPeter MacCallum Cancer Centre

Discussion

Loading...

Member takes

Implication

Key Points

Key points are not available for this paper at this time.

Cite This Study

Henneman et al. (2015) studied this question.

synapsesocial.com/papers/6a6f41c778a11c550e08f06bhttps://doi.org/10.1073/pnas.1500223112
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Gefitinib Inhibits Invasive Phenotype and Epithelial-Mesenchymal Transition in Drug-Resistant NSCLC Cells with MET Amplification2013 · 51 citations
  2. 2An integrated encyclopedia of DNA elements in the human genome2012 · 19,906 citations
  3. 3Fast and accurate short read alignment with Burrows–Wheeler transform2009 · 64,150 citations
  4. 4High sensitivity of BRCA1-deficient mammary tumors to the PARP inhibitor AZD2281 alone and in combination with platinum drugs2008 · 964 citations
  5. 5Rapid target gene validation in complex cancer mouse models using re‐derived embryonic stem cells2014 · 91 citations